The effect of OPV in that situation is not known, but might be expected to be even greater than concomitant administration given the replication kinetics of OPVs. Overall, the global plans to move from trivalent to bivalent OPVs, and eventually to inactivated poliovirus vaccines (IPV) would be expected

to have favorable effects on the immunogenicity of oral RVs in low-resource settings. A major issue emerging from rotavirus vaccine trials in high mortality/low resource settings compared with low mortality/high resource settings has been the observation of possible waning of efficacy in the second year of life. Thus, in developing world trials that include follow-up learn more time beyond the first year of life (or over multiple years) the relative person-time accumulated estimate reported during the first versus second year of life is critical to interpreting the summary point estimate of efficacy. For example, the RotaTeq® trial in Africa ended on a specific date, and so the primary outcome included

follow-up to a median of 21 months of age [5]. Thus, the overall efficacy reported in this trial reflects cases occurring at various ages. Relatively more cases during the first year of life when vaccine protection appears to be highest would Palbociclib lead to higher overall cumulative efficacy. Additionally, sites had different follow-up time and contributed cases differently to the first versus second years of life. In the RotaTeq® study in Africa, for example, the site in Mali, with lower point estimates of efficacy during both years, contributed relatively more cases in the second year of life as compared with the first year. So comparisons of efficacy beyond the first year of life are particularly problematic without a full understanding of the mix of cases by year and by site [15] and [16]. Another important element to consider when comparing results from different trials is the outcome measure. Most trials

have focused on severe gastroenteritis as measured by the Vesikari scoring system, as the primary outcome measure. Even in circumstances where the outcome is relatively uniform, how the scoring system is oxyclozanide utilized may differ between sites [17]. In addition, secondary outcome measures (e.g. efficacy according to severity of disease, all-cause gastroenteritis) may offer additional information on the public health value of a vaccine, but also require interpretation of point estimates in the context of the definitions employed. For example, in rural Kenya, multiple measures of severe gastroenteritis were used for children in the trial as a substudy of the larger multicenter RotaTeq® efficacy trial in Africa [18]. The primary outcome measure for the multicenter trial was severe gastroenteritis as measured in healthcare facilities using the 20-point modified Vesikari scoring system.